DAS28 remission and clinical efficacy in rheumatoid arthritis patients with inadequate responses to methotrexate treated with abatacept: The Phase III AIM trial and a Phase IIB trial long-term extension

被引：0
|
作者：
Westhovens, R
Kremer, J
Shergy, W
Abud-Mendoza, C
Aranda, R
Becker, JC
Zhou, Y
Mokliatchouk, O
Dougados, M
机构：
[1] Univ Hosp Gasthuisberg, Louvain, Belgium
[2] Ctr Rheumatol, Albany, NY USA
[3] Albany Med Coll, Albany, NY 12208 USA
[4] Rheumatol Assoc N Alabama, Huntsville, AL USA
[5] Hosp Cent Ignac Morones Prieto, San Luis Potosi, Mexico
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Hosp Cochin, Paris, France
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in inadequate responders to methotrexate trial.
    Kremer, J
    Westhovens, R
    Moreland, L
    Emery, P
    Russell, A
    Ge, ZY
    Aranda, R
    Becker, FC
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4095 - 4095
  • [12] An evaluation of the long-term efficacy of donepezil in patients from a Phase III clinical extension trial
    Pratt, RD
    Geldmacher, D
    Perdomo, CA
    NEUROLOGY, 1999, 52 (06) : A481 - A482
  • [13] Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
    Genant, H. K.
    Peterfy, C. G.
    Westhovens, R.
    Becker, J-C
    Aranda, R.
    Vratsanos, G.
    Teng, J.
    Kremer, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (08) : 1084 - 1089
  • [14] Abatacept provides significant and sustained benefits in clinical and patient reported outcomes through 2 yrs in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX): The long-term extension (LTE) of the aim trial
    Kremer, J. M.
    Emery, P.
    Becker, J. P.
    Aranda, R.
    Teng, J.
    Li, T.
    Westhovens, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 327 - 327
  • [15] Abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): Results from the long-term extension (LTE) of the AIM trial
    Genant, H. K.
    Peterfy, C.
    Westhovens, R.
    Becker, J. P.
    Aranda, R.
    Teng, J.
    Kremer, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 57 - 58
  • [16] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    Combe, Bernard
    Kivitz, Alan
    Tanaka, Yoshiya
    van der Heijde, Desiree
    Simon, J. Abraham
    Baraf, Herbert S. B.
    Kumar, Uma
    Matzkies, Franziska
    Bartok, Beatrix
    Ye, Lei
    Guo, Ying
    Tasset, Chantal
    Sundy, John S.
    Jahreis, Angelika
    Genovese, Mark C.
    Mozaffarian, Neelufar
    Landewe, Robert B. M.
    Bae, Sang-Cheol
    Keystone, Edward C.
    Nash, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) : 848 - 858
  • [17] Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
    van Vollenhoven, Ronald F.
    Keystone, Edward Clark
    Strand, Vibeke
    Pacheco-Tena, Cesar
    Vencovsky, Jiri
    Behrens, Frank
    Racewicz, Arthur
    Zipp, Daniela
    Rharbaoui, Faiza
    Wolter, Ralf
    Knierim, Luise
    Schmeidl, Rainer
    Zhou, Xuefei
    Aigner, Silke
    Daelken, Benjamin
    Wartenberg-Demand, Andrea
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 495 - 499
  • [18] Abatacept (ABA) slows radiographic progression over 2 yrs in rheumatoid arthritis (RA) patients (Pts) with an inadequate response to methotrexate (MTX): Results from the long-term extension (LTE) of the AIM trial
    Westhovens, R.
    Peterfy, C.
    Vratsanos, G.
    Becker, J. C.
    Aranda, R.
    Teng, J.
    Kremer, J.
    Genant, H. K.
    RHEUMATOLOGY, 2007, 46 : I15 - I16
  • [19] Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate
    Emery, P.
    Kremer, J.
    Moreland, L.
    Russell, A.
    Li, T.
    Aranda, R.
    Becker, J. C.
    Tsai, K.
    Dougados, M.
    Westhovens, R.
    RHEUMATOLOGY, 2008, 47 : II48 - II48
  • [20] Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders
    Amano, Koichi
    Matsubara, Tsukasa
    Tanaka, Takaaki
    Inoue, Hiroshi
    Iwahashi, Mitsuhiro
    Kanamono, Toshihisa
    Nakano, Teruaki
    Uchimura, Shoichi
    Izumihara, Tomomaro
    Yamazaki, Akira
    Karyekar, Chetan S.
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2015, 25 (05) : 665 - 671
12345